Analysis of the Use of Local Active Pharmaceutical Ingredients in HIV Medicine Production in Pharmaceutical Industry X
DOI:
https://doi.org/10.35451/jkg.v9i1.3758Keywords:
locally produced active pharmaceutical ingredients, HIV medicines, pharmaceutical resilience, TKDN, pharmaceutical industry, sales performanceAbstract
Background: Indonesia's dependence on imported active pharmaceutical ingredients (APIs) remains a key challenge in strengthening national pharmaceutical resilience. The government promotes locally produced APIs through domestic component level policy, domestic product prioritization, and public procurement mechanisms. However, implementation at the industry level still faces technical and economic challenges. Objective: This study explores the implementation of locally produced APIs in HIV medicine production in a national pharmaceutical company and describes its relationship with input, process, and output factors, represented by product sales performance. Methods: This non-experimental case study used a qualitative approach through in-depth interviews, supported by descriptive quantitative analysis. Eight professionals from R&D, quality assurance/manufacturing, costing/finance, and commercial functions were interviewed. Secondary data were obtained from company documents, IQVIA market data from 2020 to 2024, and relevant regulations. Results: Locally produced APIs increased the domestic component level and strengthened product positioning in government procurement. Nevertheless, most locally produced APIs were more expensive than imported APIs, increasing the cost of goods manufactured by approximately 2.0%-28.9%. All analyzed products generated positive gross margins, ranging from 19% to 68%. From a process perspective, local API utilization required raw material characterization, formulation evaluation, stability/dissolution/bioequivalence testing when needed, process validation, and quality control. Conclusion: Local APIs provide strategic value for pharmaceutical resilience and government market access, but their sustainability depends on balanced support for quality, price, supply continuity, industrial technical readiness, and procurement policies that do not rely solely on the lowest price.
Downloads
References
[1] World Health Organization, Everybody's Business: Strengthening Health Systems to Improve Health Outcomes: WHO's Framework for Action. Geneva, Switzerland: World Health Organization, 2007.
[2] Kementerian Kesehatan Republik Indonesia, Laporan Kinerja Direktorat Ketahanan Farmasi dan Alat Kesehatan Tahun 2025. Jakarta, Indonesia: Kementerian Kesehatan Republik Indonesia, 2025.
[3] E. Hermawan, N. A. Hadiyati, A. Adiarso, E. D. Setiyadi, S. Zunuraen, D. Hidayat, A. Wahyudi, and H. A. Ru'yi, "Challenges and policy supports in Indonesian pharmaceutical raw materials industry," Jurnal Administrasi Kesehatan Indonesia, vol. 11, no. 2, pp. 196-211, 2023, doi: 10.20473/jaki.v11i2.2023.196-211.
[4] P. J. Guerin, S. Singh-Phulgenda, and N. Strub-Wourgaft, "The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?" F1000Research, vol. 9, p. 225, 2020, doi: 10.12688/f1000research.23057.1.
[5] A. Goswami, A. Baveja, X. Ding, B. Melamed, and F. Roberts, "An integrated framework for modeling pharmaceutical supply chains with disruptions and risk mitigation," Annals of Operations Research, 2024, doi: 10.1007/s10479-024-06381-y.
[6] Kementerian Kesehatan Republik Indonesia, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1333/2023 tentang Peningkatan Penggunaan Sediaan Farmasi. Jakarta, Indonesia: Kementerian Kesehatan Republik Indonesia, 2023.
[7] Kementerian Perindustrian Republik Indonesia, Peraturan Menteri Perindustrian Nomor 16 Tahun 2020 tentang Ketentuan dan Tata Cara Penghitungan Nilai Tingkat Komponen Dalam Negeri Produk Farmasi. Jakarta, Indonesia: Kementerian Perindustrian Republik Indonesia, 2020.
[8] S. Satibi, L. K. Kirana P, M. Aziza P, M. Hutasoit, and P. Pribadi, "Analysis of e-catalogue drug prices in the era of Universal Health Coverage in the Indonesian pharmaceutical industry," Pharmacia, vol. 69, no. 2, pp. 555-562, 2022, doi: 10.3897/pharmacia.69.e83068.
[9] World Health Organization, Update of Recommendations on First- and Second-Line Antiretroviral Regimens. Geneva, Switzerland: World Health Organization, 2019.
[10] UNAIDS, UNAIDS Global AIDS Update 2025: AIDS, Crisis and the Power to Transform. Geneva, Switzerland: United Nations, 2025.
[11] Kementerian Kesehatan Republik Indonesia, Petunjuk Teknis Rencana Kebutuhan Obat. Jakarta, Indonesia: Kementerian Kesehatan Republik Indonesia, 2024.
[12] A. K. Nair and U. Mangal, "Impact of API (Active Pharmaceutical Ingredient) source selection on generic drug products," Pharmaceutical Regulatory Affairs: Open Access, vol. 4, no. 2, 2015, doi: 10.4172/2167-7689.1000136.
[13] F. Stauffer, V. Vanhoorne, G. Pilcer, P.-F. Chavez, S. Rome, M. A. Schubert, L. Aerts, and T. De Beer, "Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing," European Journal of Pharmaceutics and Biopharmaceutics, vol. 127, pp. 92-103, 2018, doi: 10.1016/j.ejpb.2018.02.017.
[14] S. C. Gad, Ed., Pharmaceutical Manufacturing Handbook: Production and Processes. Hoboken, NJ, USA: Wiley-Interscience, 2008.
[15] World Health Organization, WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva, Switzerland: World Health Organization, 2010.
[16] IQVIA, J05C HIV Antivirals Market Data, MAT Q4 2024. Proprietary market data, 2024.
[17] L. von Bertalanffy, General System Theory: Foundations, Development, Applications. New York, NY, USA: Braziller, 2009.
[18] C. T. Horngren, G. Foster, S. M. Datar, M. Rajan, M. Ittner, and A. A. Baldwin, "Cost accounting: A managerial emphasis," Issues in Accounting Education, vol. 25, no. 4, pp. 789-790, 2010, doi: 10.2308/iace.2010.25.4.789.
[19] H. Lim and R. Rokhim, "Factors affecting profitability of pharmaceutical company: An Indonesian evidence," Journal of Economic Studies, vol. 48, no. 5, pp. 981-995, 2021, doi: 10.1108/JES-01-2020-0021.
[20] R. Wasir, S. Irawati, A. Makady, M. Postma, W. Goettsch, E. Buskens, and T. Feenstra, "Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia," PLOS ONE, vol. 14, no. 2, e0212328, 2019, doi: 10.1371/journal.pone.0212328.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Muhamad Ulfi Bahari, Puput Oktamianti
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright in each article is the property of the Author.
